36 th Annual JP Morgan Healthcare Conference Mike Mahoney Chairman - - PowerPoint PPT Presentation

36 th annual jp morgan healthcare conference
SMART_READER_LITE
LIVE PREVIEW

36 th Annual JP Morgan Healthcare Conference Mike Mahoney Chairman - - PowerPoint PPT Presentation

36 th Annual JP Morgan Healthcare Conference Mike Mahoney Chairman & Chief Executive Officer Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities


slide-1
SLIDE 1

36th Annual JP Morgan Healthcare Conference

Mike Mahoney

Chairman & Chief Executive Officer

slide-2
SLIDE 2

2

Safe Harbor for Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could differ materially from the expectations and projections expressed or implied by our forward-looking statements. Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings “Risk Factors” and “Safe Harbor for Forward-Looking Statements.” Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. Non-GAAP Measures: This document contains non-GAAP measures (denoted with *) in talking about our company’s performance. The reconciliations of those non- GAAP measures to their most comparable GAAP measures are contained within this document including appendices attached to the end of this presentation. Financial Disclaimers: Operational growth rates are non-GAAP measures that exclude the impact of changes in foreign currency exchange rates. Organic growth rates are non-GAAP measures that exclude the impact of changes in foreign currency exchange rates and the sales from significant acquisitions (Symetis SA, the American Medical Systems male urology portfolio and EndoChoice Holdings, Inc.) in the relevant periods. We define Emerging Markets as including certain countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Currently, we have 20 countries in our definition of Emerging Markets. Market Estimates: Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates.

slide-3
SLIDE 3

3

Regulatory Disclaimers

Product Regulatory Disclaimer Implantable Cardiac Monitor Device under development. Not available for use or sale worldwide. EMPOWER™ Leadless Pacer Device under development. Not available for use or sale worldwide. Apama RF Balloon Catheter Device under development. Not available for use or sale worldwide. DrectSense™ Technology Device under development. Not available for use or sale worldwide. Ranger™ Drug-Coated Balloon CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale. Drug Eluting Stent – Below-the-knee indication Device under development. Not available for use or sale worldwide. Eluvia™ Drug eluting self-expanding SFA stent CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale. Lotus Edge™ U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale. ACURATE™ Self Expanding Valve Platform CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale. WATCHMAN™ FLX Pending CE Mark. Not available for use or sale in the U.S.

slide-4
SLIDE 4

4

Our Mission and Values

Caring Meaningful Innovation High Performance Global Collaboration Diversity Winning Spirit

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health

  • f patients around the world.
slide-5
SLIDE 5

5

What to Expect from BSX

  • Track record of delivering revenue and EPS growth faster than peer group

– Q4 2017 sales growth1: 8% operational*, 7% organic* vs Q4 2016 organic* comp of 10% – FY 2017 sales growth1: 8% operational*, 7% organic* vs FY 2016 organic* comp of 10% – FY 2017 profitability and EPS2: +100 bps adj. OM*, +11-14 adj. EPS growth* – 2015-2017E: organic revenue* CAGR1 +7% and adjusted EPS CAGR2 +14-15%

  • Driving category leadership and expanding globally with scale & capabilities in emerging markets

– Gaining share globally via portfolio innovation and economic value drivers

  • Diversified & durable growth profile + investing to lead in multiple new high growth markets

– Diversified portfolio today + entering new high-growth markets totaling ~$15B in 2021E

  • Strong execution and shareholder value creation: More to come in 2018-2020 and beyond

– 2018E-20E: organic rev.* CAGR +5-8%, adj. OM* gains, flat mid-teens tax rate, EPS CAGR +DD – Strong adj. free cash flow*: est. $6.3B cumulative in years 2018-2020 with limited contingencies

slide-6
SLIDE 6

6

$0.3B, +14%

Boston Scientific At-A-Glance

2017 Revenue1 and Operational Growth1*: (Total company: $9.0B, 8%; Organic Growth* 7%)

Rhythm Management Interventional Cardiology Structural Heart Peripheral Interventions

$2.4B, +6% $1.1B, +7% $275M+2

CRM Electrophysiology

$1.9B, +2%

Endoscopy Urology & Pelvic Health Neuromodulation

$1.6B, +12% $0.6B, +14% $1.1B, +12%

slide-7
SLIDE 7

7

Reported Revenue, Y/Y operational* growth Y/Y Organic* growth rates 18.9% 20.2% 22.3% 24.1% 2013 2014 2015 2016 2017E 25% – 25.25% $7.1 $7.4 $7.5 $8.4 $9.0 2013 2014 2015 2016 2017 +2% +6% +8% +12% +8% +4% +5% +10% +7% $0.73 $0.84 $0.93 $1.11 2013 2014 2015 2016 2017E +11% +15% +11% +20% +11%

  • 14%

$1.24 - $1.27

High Performance Culture and Track Record

Adjusted EPS* Revenue Adjusted Operating Margin*

Sales growth consistent > mkt 7% organic CAGR ’15-’17E Delivering on margin expansion goals Consistent double digit EPS growth: 14-15% CAGR ’15-’17E

1 2 2

slide-8
SLIDE 8

8

Diversified in Large Global Markets While Investing in Higher Growth Segments

Business

2017E Market Size 2017E Market Growth 2020E Market Size ’17 - ’20E Market CAGR

Key Investment Areas, New Markets

Cardiovascular Cardiology $7.5B 1% $8B 0-1% Complex PCI, PCI Guidance, Heart Failure Structural Heart $4B 21% $6B 15-20% TAVR, LAAC, Mitral Replace & Repair Peripheral $6B 6% $7.5B 6-8% Drug-Eluting, Oncology, Venous, CLI Rhythm Mgmt. CRM + Diagnostics $10B 1% $10B 0-2% S-ICD/Leadless, Diagnostics, Heart Failure EP $4B 12% $6B 9-11% Mapping, Navigation, Therapeutic Solutions MedSurg Endoscopy $5B 5% $6B 5-6% Endo-Luminal Surgery, Visualization, Pulmonary Urology & PH $3.5B 5% $4.5B 5-6% Stone, Prostate, ER, OAB, Globalization Neuromodulation $3B 14% $4B 10-15% Pain, Brain, Movement Disorders WW Total ~$43B 4-5% ~$50B 5-6% Continuing to invest in higher growth areas

slide-9
SLIDE 9

9

2017 Sales1 Market ~ 2021E Growth Accelerators

$275M+ ~$6B

  • WATCHMAN global expansion
  • ACURATE – TAVR
  • LOTUS – TAVR

~$50M ~$2B

  • Visualization
  • Cancer
  • Overactive Bladder

~$50M ~$2B

  • Pathology
  • Infection Prevention
  • Endo-Luminal Surgery

40%+ growth ~$1B

  • DBS for PD, Tremor
  • Other indications 2020+

~$50M ~$2B

  • Eluvia – DES
  • Ranger – DCB
  • Critical Limb Ischemia (CLI)

IC: TAVR + LAAC PI Drug Eluting Endo new markets Uro/PH new markets Neuromod - Brain

~$15B <$500M

  • ~$2B

Rhythm Management

  • Apama RF PVI Balloon for AFib
  • Implantable Cardiac Monitor (ICM)
  • HeartLogic™ Heart Failure Alert

Expanding Today into Multiple New High Growth Markets That Approach ~$15B 2021E

slide-10
SLIDE 10

10

Urology and Pelvic Health Neuromodulation Endoscopy

Vercise™ Deep Brain Stimulation Platform 1st directional system for Parkinson’s, dystonia, & tremor globally Spectra WaveWriter ™ SCS System First platform to combine paresthesia and sub- perception therapies Additional investments for therapies in stroke and Alzheimer’s Disease Biliary Leadership Leveraging clinical innovations and core portfolio iterations Endo-Luminal Surgery Emerging alternative to surgical resection; initial focus on GI tract cancers SpyGlass DS™ Visualization Minimally invasive, single- use digital cholangioscope Women’s Health Expanding portfolio technologies & global footprint Men’s Health & BPH Greenlight XPS ™ Laser Therapy System Category leadership, market & geographic expansion Stone Disease & LithoVue™ Single-Use Ureteroscope Leading platform, next gen technology, and expanding globally

MedSurg: Category Leadership & Growth Drivers

Infection Prevention & Pathology Services Solutions for Ambulatory Surgery Center market

slide-11
SLIDE 11

11

Cardiovascular: Category Leadership & Growth Drivers

Peripheral Interventions Interventional Cardiology Structural Heart

Complex PCI Multiple new product launches in key growth areas Synergy™ & line extensions Continued DES leadership Polaris™: IVUS & Comet™ FFR Global leader in IVUS and expanding into FFR market Mitral Valve Replace & Repair Future focus area TAVR Portfolio

  • ACURATE AS ™ supra-

annular , top-down deployment

  • LOTUS Edge™ intra-

annular, fully reversible Watchman™ LAAC Device Expanding utilization & market indications Interventional Oncology Portfolio additions + significant opportunity in Emerging Markets AngioJet Zelante ™ DVT Catheter Foundation for complete venous portfolio Comprehensive Drug- eluting Technologies

  • Eluvia ™ DES built

for the SFA

  • Ranger ™ DCB
  • Pursuing DES for CLI
slide-12
SLIDE 12

12

Rhythm Management: Category Leadership & Growth Drivers

Electrophysiology Core CRM Diagnostics

Emblem™ MRI S-ICD Continued positive

  • utcomes and ongoing

clinical science Resonate ™ HV Family Next gen platform compatible with HeartLogic™ plus EnduraLife, MSP and MRI mCRM ™ Modular CRM: EMBLEM™ S-ICD with EMPOWER™ leadless pacer Connected Patients Portfolio of cardiac monitoring products and services Implantable Cardiac Monitor Developing arrhythmia monitoring device HeartLogic™ Drive share with 70% sensitivity in detecting HF events at median 34 days prior to event Apama RF PVI Balloon Catheter System Differentiated, multi- electrode, single shot RF therapy for pulmonary vein isolation Therapeutic Catheters

  • DirectSense™

technology

  • Force Sensing

technology Rhythmia™ HDx Second gen mapping & navigation platform

slide-13
SLIDE 13

13

Strong Product Pipeline Supports Long Range Plan Growth Targets

2020E / 2021E

Coronary Therapies

  • Synergy DES line extensions

Structural Heart

  • WATCHMAN FLX – U.S.
  • ACURATE neo AS – U.S./Japan
  • ACURATE – size matrix expansion
  • **LOTUS size matrix expansion

Peripheral Interventions

  • Ranger SFA DCB – U.S.
  • Drug eluting stent – Critical Limb Ischemia

CRM/EP

  • Leadless Pacing/modular CRM – EU
  • Force Sensing Catheter – U.S.

Endo

  • EUS Guided Pulmonary BX – U.S./EU
  • Axios expanded Indications – U.S.

Urology/Pelvic Health

  • Multiple launches in Stone
  • Multiple launches in Men’s Health
  • Next Gen Greenlight fiber for BPH

NMD

  • SCS & DBS Next Gen – U.S./EU

2018E 2019E

Coronary Therapies

  • Synergy DES line extensions
  • Multiple launches in Complex PCI

Structural Heart

  • WATCHMAN FLX – EU
  • WATCHMAN – Japan
  • ACURATE – Int’l expansion
  • **LOTUS U.S. & EU

Peripheral Interventions

  • Eluvia SFA DES - U.S.
  • Interventional Oncology Embolic Coils

CRM/EP

  • ICM Monitoring & Dx
  • Force Sensing Catheter – EU
  • Apama RF PVI Balloon – EU

Endo

  • SpyGlass Next Gen

Urology/Pelvic Health

  • LithoVue Next Gen
  • 5 additional launches in Stone

Neuromodulation

  • Expanded DBS platform

Coronary Therapies

  • 5 launches in Complex PCI

Structural Heart

  • ACURATE – OUS Expansion
  • ACURATE neo AS – EU

CRM/EP

  • Resonate with HeartLogic HF Alert
  • Rhythmia HDx w/ LUMIPOINT ™
  • DirectSense Rx Catheter – EU/U.S.

Endoscopy

  • Endo-Luminal Surgery tools
  • Axios Transluminal Stent – Japan

Urology/Pelvic Health

  • 4 launches in Stone

Neuromodulation

  • WaveWriter SCS System
  • Vercise DBS system – U.S.

**Intend to launch Lotus in the U.S. & EU in 2019 pending final testing & regulatory approvals

slide-14
SLIDE 14

14

Estimated Market Growth Rates

Diversified and Durable Growth Profile

Low Growth 35% Moderate Growth 50% Low Growth 46% Moderate Growth 47%

2017 Revenue Mix1 $9.0B 2020E Revenue Mix 2012 Revenue Mix $7.2B

High Growth Mkt (10%+ CAGR): SCS, TAVR, LAAC, EP, DBS, PI Drug Eluting, ICM

High Growth 7% High Growth 15%

Low Growth 25% Moderate Growth 50% High Growth 25%

Low Growth Mkt (0 - 3% CAGR): Pacers, Defibrillators, DES Moderate Growth Mkt (4 - 9% CAGR): Endo, UroPH, PI (ex DES & DCB), Int. Oncology, IC (ex. SH, DES)

slide-15
SLIDE 15

15

Emerging Markets Partnerships

China & India: Partnerships & VC investments Latin America: Expanding access

Emerging Markets Estimated to Exceed $1B in 2018 and Drive ~150bps Growth thru 2020E

2013 2017E 2020E

$625M $900M $1.4B

Emerging Markets Operational Revenue* Emerging Markets Growth Drivers & Key Capabilities

  • Global orientation
  • New launches, portfolio

registration

  • Expanding commercial

capabilities

  • Portfolio diversification
  • New R&D and physician training

capabilities

  • New Malaysia manufacturing and

distribution facility

Tsinghua University

Ca Cardio dioYA

Seguridad y calidad, de corazón

1

slide-16
SLIDE 16

16

Compelling opportunity beyond 2020 for 30%+ adjusted OM*

2013 2014 2015 2016 2017E2 2020E 25%- 25.25% 24.1% 30+% 22.3% 20.2% 18.9%

~+300 bps

SG&A productivity Accretive new products Launches & commercial scale

  • f key products

R&D efficiencies 5-10% annual standard cost improvements

Track Record of Driving Operating Margin Expansion AND Significant Future Opportunity

28% Longer Term Goal

slide-17
SLIDE 17

17

Strong Cash Flow Generation Outlook AND Limited Reserved Contingencies 2018-2020E

Strong Free Cash Flow*: 2016-2020E Improved Ability to Deploy Cumulative Free Cash Flow*

** Based on adjusted free cash flow. Refer to non-GAAP reconciliations

80% 90%

2015-2017E: ~$4.8B 2018E-2020E: ~$6.3B

10%

Reserved Contingencies** M&A or Returning Cash to Shareholders

20% 10%

2016 2017E 2018E 2019E 2020E

$1.6B ~$1.75B ~$1.9B ~$2.1B ~$2.3B

slide-18
SLIDE 18

18

Post Tax Reform Estimated Effective Tax Rate*

2017E 2018E 2019E 2020E 2023E

Tax Reform Impact Brings Greater Financial Flexibility AND Increased Earnings Power

Full access to OUS cash

All estimated tax rates are adjusted and exclude discrete tax items, such as the benefit related to adoption of ASU 2016-09

  • Greater financial flexibility
  • Increased earnings power

Pre Tax Reform Expected Effective Tax Rate*

Full access to OUS cash through 2018

Partial access to OUS cash 2019+

15% 16% 17% 20% 2017E 2018E 2019E 2020E 2023E 14%

Expected increase of 100 bps per year for access to OUS cash

14% ~16% ~15%

slide-19
SLIDE 19

19

2017E 2015-2017E CAGR Goals 2018E Goals 2019 & 2020E 2018E-2020E CAGR Organic Revenue* 7% 1 +7% +5-6% +5-8% +5-8% Operational Revenue* 8% 1 +9%

  • - Est. additional +100 bps --

+6-9% Adjusted

  • Op. Margin*

25%-25.25% 2 ~175 bps

Improvement annually

+50-75bps

w/MDET repeal

+~25bps

w/MDET reinstated

~100+ bps

Improvement annually

28% in 2020 Effective Tax Rate* 14% 2 ~16% ~15% Adjusted EPS* Growth 11%-14% 2 +14-15%

Consistent and Strong Financial Outlook

  • ------Double digit goal --------
slide-20
SLIDE 20

20

What to Expect from BSX

  • Track record of delivering revenue and EPS growth faster than peer group

– Q4 2017 sales growth1: 8% operational* , 7% organic* vs Q4 2016 organic* comp of 10% – FY 2017 sales growth1: 8% operational*, 7% organic* vs FY 2016 organic* comp of 10% – FY 2017 profitability and EPS2: +100 bps adj. OM*, +11-14 adj. EPS growth* – 2015-2017E: organic revenue* CAGR1 +7% and adjusted EPS CAGR2 +14-15%

  • Driving category leadership and expanding globally with scale & capabilities in emerging markets

– Gaining share globally via portfolio innovation and economic value drivers

  • Diversified & durable growth profile + investing to lead in multiple new high growth markets

– Diversified portfolio today + entering new high-growth markets totaling ~$15B in 2021E

  • Strong execution and shareholder value creation: More to come in 2018-2020 and beyond

– 2018E-20E: organic rev.* CAGR +5-8%, adj. OM* gains, flat mid-teens tax rate, EPS CAGR +DD – Strong adj. free cash flow*: est. $6.3B cumulative in years 2018-2020 with limited contingencies

slide-21
SLIDE 21

21

Recent Awards and Recognitions Reflect Winning Spirit Culture that Drives Results

Recognized for progressive life/work policies and programs Ranked #35 based on employee ratings Ranked #16 in the U.S. Ranked #3 on U.S. Large Company list Scored 100% for the 4th consecutive year Scored 100% for the 2nd year in a row Highest recognition for Guard/Reserve employee support Ranked 6th in industry category

slide-22
SLIDE 22

22

Appendix A

Detailed Growth Drivers by Business

slide-23
SLIDE 23

23

Endoscopy: Category Leadership & Growth Drivers

Overview BSX Growth Drivers

  • Cholangioscopy acceleration

SpyGlass DS is the first and only minimally invasive, single use, single operator digital cholangioscope

  • GI-focused pathology solutions

GI specialized pathology services and dedicated commercial team servicing $600M ASC opportunity

  • Infection prevention expansion

Enhanced safety for patients and healthcare providers in $775M global market

  • Endo-Luminal Surgery replacing open procedures

Safer, less costly, minimally invasive alternatives to traditional surgery

  • Growing leadership in Endoscopic Ultrasound (EUS) therapeutics

Portfolio expansion and new indications for Axios, the world’s first transluminal stent

Market Size (2017E) ~$3B Market Growth (2017E) +5% 2017-2020

  • est. CAGR

+5%-6% BSX 20171

Operational Growth*

+12% Share Position #1

slide-24
SLIDE 24

24

Urology and Pelvic Health: Category Leadership & Growth Drivers

Overview BSX Growth Drivers

  • Innovate across all franchises

Add to our core portfolio along with developing clinical and economic evidence; evolve commercial model to meet demands of global healthcare market

  • Expand globally

Lead with stone portfolio to gain critical mass and commercial presence; then selectively launch additional franchises in regional markets

  • Enter attractive adjacent markets

Evolve our portfolio with new adjacencies and tools that add value beyond our current portfolio, differentiated by excellent medical education

Market Size (2017E) ~$3.5B Market Growth (2017E) +5% 2017-2020

  • est. CAGR

+5%-6% BSX 20171

Operational Growth*

+12% Share Position #1

slide-25
SLIDE 25

25

Neuromodulation: Category Leadership & Growth Drivers

Overview BSX Growth Drivers

  • Spectra Wavewriter ™ SCS System

First and only SCS system able to combine paresthesia and sub-perception therapies

  • Comprehensive SCS Platform with MultiWave ™

Personalized therapy with neural targeting algorithm (Illumina 3D ™) and lead portfolio

  • Cosman RF Ablation

Treatment options for pain patients

  • Vercise ™ Deep Brain Stimulation Platform

First MICC-based directional system

  • International expansion

Under-penetrated market opportunity in both pain and brain

Market Size (2017E) ~$2.5B Market Growth (2017E) +14% 2017-2020

  • est. CAGR

+10%-15% BSX 20171

Operational Growth*

+14% Share Position #2

slide-26
SLIDE 26

26

Coronary Therapies: Category Leadership & Growth Drivers

Overview BSX Growth Drivers

  • Coronary Therapies

Diversify coronary revenue to higher growth, less price sensitive product lines through portfolio execution

  • Stents

Protect DES leadership position with tiered portfolio and Synergy line extensions

  • Complex PCI

Multiple launches of new Complex PCI specialty products

  • PCI Guidance

Expand footprint into $400M FFR market and maintain leadership in IVUS

Market Size (2017E) ~$7.5B Market Growth (2017E) +1% 2017-2020

  • est. CAGR

+0%-1% BSX 20171

Operational Growth*

+6%

(including SH)

Share Position #1

slide-27
SLIDE 27

27

Structural Heart: Category Leadership & Growth Drivers

Overview BSX Growth Drivers

  • Watchman™ LAAC Device

Expanding market with excellent outcomes, therapy development and expanding indications

  • ACURATE neo™ Aortic Valve System

Global expansion through commercial integration, a unique feature set and outstanding clinical outcomes

  • LOTUS Edge™ Aortic Valve System

Differentiated TAVR platform providing complete control and lowest PVL

  • Mitral Replace and Repair

Expand valve portfolio into $3B potential new market

  • pportunity

Market Size (2017E w/Mitral) ~$4B Market Growth (2017E) +21% 2017-2020

  • est. CAGR

+15%-20% Share Position #3

slide-28
SLIDE 28

28

Peripheral Interventions: Category Leadership & Growth Drivers

Overview BSX Growth Drivers

  • Drug Eluting Technologies for PAD

Differentiated portfolio backed by unparalleled clinical program

  • Expanding Interventional Oncology Solutions

Significant opportunity in Emerging Markets

  • Complete Deep Venous Portfolio

Large, underpenetrated market

  • Critical Limb Ischemia

Only company pursuing DES Below The Knee

  • Breadth of portfolio across disease states

Mindshare with physicians and contracting advantage

Market Size (2017E) ~$6B Market Growth (2017E) +6% 2017-2020

  • est. CAGR

+6%-8% BSX 20171

Operational Growth*

+7% Share Position #1

slide-29
SLIDE 29

29

Cardiac Rhythm Management: Category Leadership & Growth Drivers

Overview BSX Growth Drivers

  • RESONATE ™ HV Family of Devices

Next gen platform with HeartLogic™ Heart Failure Alert, MRI, MSP (CRT-D), and EnduraLife

  • HeartLogic Heart Failure Alert

Drive share with diagnostic that offers 70% sensitivity in detecting HF events at median 34 days prior to event

  • EMBLEM™ MRI S-ICD

First and only S-ICD with continued positive outcomes and

  • ngoing clinical science
  • mCRM™ (modular CRM)

EMBLEM ™ S-ICD with EMPOWER ™ leadless pacer

  • Implantable Cardiac Monitor

Diagnostic-only device – target launch H1:2019E

Market Size (2017E) ~$10B Market Growth (2017E) 1% 2017-2020

  • est. CAGR

0%-2% BSX 20171

Operational Growth*

+2% Share Position WW #3 US #2

slide-30
SLIDE 30

30

Electrophysiology: Category Leadership & Growth Drivers

Overview BSX Growth Drivers

  • RHYTHMIA HDx ™ System

Second gen Mapping and Navigation system Rhythmia HDx with LUMIPOINT ™ software module

  • Navigation and MiFi Ablation Catheters

Full portfolio of navigation and non-navigation enabled therapeutic catheters

  • DirectSense™ Technology

Launching now in Europe and H1:2018E in the US

  • Force Sensing Technology

Expands therapeutic portfolio in $800M market opportunity – EU launch 2019E

  • Apama RF PVI Balloon Catheter System

Differentiated, multi-electrode single shot RF therapy to address fast growing ~$500M market

Market Size (2017E) ~$4B Market Growth (2017E) +12% 2017-2020

  • est. CAGR

+9%-11% BSX 20171

Operational Growth*

+14% Share Position #4

slide-31
SLIDE 31

31

Appendix B

References and Non-GAAP Reconciliations

slide-32
SLIDE 32

32

References

*Non-GAAP measure; for reconciliations of non-GAAP financial measures to the most directly comparable GAAP figures, please refer to Appendix A of this document.

1Based on preliminary, unaudited sales results issued January 9, 2018 2Based on guidance issued October 26, 2017

slide-33
SLIDE 33

33

Supplemental Non-GAAP Disclosures

(Low) (High) (Low) (High) Estimated GAAP EPS $0.71 $0.75 180% 196% Estimated acquisition-related net charges 0.01 0.00 Estimated restructuring and restructuring-related charges 0.06 0.06 Estimated amortization expense 0.35 0.35 Investment impairment charges 0.02 0.02 Litigation-related charges 0.09 0.09 Estimated Adjusted EPS $1.24 $1.27 11% 14% Less: Estimated impact of foreign currency fluctuations

  • 0.08
  • 0.07
  • 7%
  • 7%

Estimated Adjusted EPS, excluding FX $1.32 $1.34 18% 21% Full Year 2017 Estimate Estimated Growth

Revenue Growth Q4 20171 Q4 2016 Revenue growth, as reported 9.9% 11% Less: Impact of foreign currency fluctuations 1.8% 0% Operational Revenue Growth 8.1% 11% Less: Impact of significant acquisitions 3.0% 1% Organic Revenue Growth 6.8% 10%

Revenue Growth 2015-20171 (CAGR) 20171 2016 2015 2014 2013 Revenue growth, as reported 7% 7.9% 12% 1% 3%

  • 1%

Less: Impact of foreign currency fluctuations

  • 2%

0.1% 0%

  • 7%
  • 3%
  • 3%

Operational Revenue Growth 9% 7.8% 12% 8% 6% 2% Less: Impact of significant acquisitions 2% 1.2% 2% 3% 2% Organic Revenue Growth 7% 6.6% 10% 5% 4%

slide-34
SLIDE 34

34

Supplemental Non-GAAP Disclosures

slide-35
SLIDE 35

35

Supplemental Non-GAAP Disclosures

Interv entional Cardiology 6.2% 0.1% 6.1% Peripheral Interv entions 6.5%

  • 0.1%

6.6% Cardiovascular 6.3% 0.0% 6.3% Cardiac Rhythm Management 2.5% 0.2% 2.3% Electrophysiology 14.5% 0.1% 14.4% Rhythm Management 3.9% 0.2% 3.7% Endoscopy 12.4% 0.1% 12.3% Urology & Pelv ic Health 11.8% 0.2% 11.6% Neuromodulation 14.2% 0.1% 14.1% MedSurg 12.5% 0.1% 12.4% Total Company 7.9% 0.1% 7.8% 1.2% 6.6% Revenue (in billions ) As Reported Less: FX Impact Operational* Total Company 9.0

  • 0.1

9.1 FY2017 Preliminary / Unaudited Net Sales FY2017 Preliminary / Unaudited Net Sales Growth as compared to FY2016 As Reported Less: Impact of Foreign Currency Operational* Less: Impact of Significant Acquisitions Organic*

slide-36
SLIDE 36

36

Supplemental Non-GAAP Disclosures

Emerging Markets Revenue (in millions) 2013 Revenue, as reported 589 $ Less: Impact of foreign currency fluctuations (36) Operational Revenue 625 $ Emerging Markets Revenue (in millions) 2017E Estimated Revenue, reported 917 $ Less: Impact of foreign currency fluctuations (8) Estimated Operational Revenue 925 $ Emerging Markets Revenue (in billions) 2020E Estimated Revenue, reported 1.4 $ Less: Impact of foreign currency fluctuations

  • Estimated Operational Revenue

1.4 $ Emerging Market Revenue CAGR 2017E-2020E 15%

slide-37
SLIDE 37

37

The following is an explanation of the adjustments that management excluded from GAAP measures to calculate the following forward-looking non-GAAP financial measures: Adjusted Gross Margin: Excludes from GAAP gross margin the impacts of forecasted acquisition- and divestiture- and restructuring-related charges or credits. Adjusted SG&A: Excludes from GAAP SG&A the impacts of forecasted acquisition- and divestiture- and restructuring-related charges or credits. Adjusted R&D: Excludes from GAAP R&D the impacts of forecasted acquisition- and divestiture- and restructuring-related charges or credits. Adjusted Operating Margin: Excludes from GAAP operating margin the impacts of forecasted acquisition- and divestiture- and restructuring- and restructuring-related charges or credits, and amortization expense. Adjusted Tax Rate: Excludes from GAAP tax rate the tax impacts related to forecasted acquisition- and divestiture- and restructuring- and restructuring-related charges or credits, and amortization expense. Adjusted Free Cash Flow: Adjusts GAAP operating cash flow to include the impacts of forecasted capital expenditures and excludes the impact of estimated after-tax acquisition- and divestiture-, restructuring- and litigation-payments. Please refer to our Safe Harbor for forward-looking statements disclosure in conjunction with any forward looking information presented within.

Supplemental Non-GAAP Disclosures